In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Selumetinib is used to treat type 1 neurofibromatosis (NF1) in pediatric patient···【more】
Release date:2026-02-10Recommended:220
Selumetinib is used to treat patients with neurofibromatosis type 1 (NF1) with p···【more】
Release date:2026-02-10Recommended:235
The dosage of this medicine is individualized. Please follow the doctor’s instru···【more】
Release date:2026-02-09Recommended:303
Sparsentan is indicated for slowing the progression of renal function decline in···【more】
Release date:2026-02-09Recommended:330
The dosage of sparsentan is individualized; please use it in accordance with you···【more】
Release date:2026-02-09Recommended:298
Sparsentan is indicated for slowing the decline in renal function in adult patie···【more】
Release date:2026-02-09Recommended:275
Belzutifan produced by Lucius Pharmaceuticals is a bioequivalent generic drug wi···【more】
Release date:2026-02-06Recommended:204
The version of belzutifan produced by Lucius Pharmaceuticals is a more cost-effe···【more】
Release date:2026-02-06Recommended:238
Belzutifan is an oral targeted drug of the hypoxia-inducible factor-2α (HIF-2α) ···【more】
Release date:2026-02-06Recommended:259
Belzutifan is a hypoxia-inducible factor (HIF) inhibitor. It exerts its effect b···【more】
Release date:2026-02-06Recommended:259
Doctors should conduct regular follow-ups to evaluate the efficacy of the medica···【more】
Release date:2026-02-05Recommended:181
After administration, necessary therapeutic effects may occur, and adverse react···【more】
Release date:2026-02-05Recommended:199